Heico Breek

TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium.

Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ.

Cavadis BV discovers biomarkers for progression of atherosclerotic disease. The firm’s product series include pipeline, medical need, market potential and personalized medicine. The company was founded in 2007 by Ronald Nanninga and Oscar Schoots and is headquartered in Hilversum, the Netherlands.

ACS Biomarker BV develops and commercializes cardiovascular biomarkers. The firm offers miRNA profiling services. It engages in the discovery, validation, and commercialization of biomarkers that improve diagnosis, prognosis and management of cardiac diseases. The company was founded in 2007 by Mat J. A. P. Daemen, Yigal M. Pinto and Tilman Hackeng and is headquartered in Maastricht, the Netherlands.

Encapson BV operates as a medical device technology company. It specializes in the use of polymer-based capsules for microencapsulation. The company's products include Capsol, a paclitaxol delivery method for drug eluting balloons; and Sono-coat, an echogenic coating that is applied for biopsy and anesthesiology needles, brachytherapy needles, guiding and embryo transfer catheters, and drainage catheters. Encapson was founded by Lee Ayres and Dennis Manuel Vriezema in 2005 and is headquartered in Enschede, the Netherlands.

MirNext BV focuses on the discovery, validation and commercialization of microRNAs as novel biomarkers for cardiovascular disease. Its multiple circulating miRNAs act as informative markers for the diagnosis of heart failure, coronary artery disease, and myocardial infarction, as well as used to predict cardiovascular risk, such as mortality and hospitalization. The company was founded in 2012 and is headquartered in Amsterdam, the Netherlands.